



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 09/30/2022 15:48  
**Last Report Issued** 09/14/2022 07:07

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** NA  
**Patient ID** 2505B-POS  
**Chain** 22002163  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 22002163  
**Received** 09/14/2022

**Lab ID** 22002163-001  
**Matrix** Blood  
**Patient Name** NA  
**Patient ID** 2505B-POS  
**Container Type** Black Cap Glass Container

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2505B Levetiracetam, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Levetiracetam	10	mcg/mL	1.0	
Synonym(s): Kepra®				

Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1-33 mcg/mL. The blood to plasma ratio is approximately 0.9.

This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.